Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Barbone, Dario ^a   Cheung, Priscilla ^a   Battula, Sailaja ^a   Busacca, Sara ^b   Gray, Steven G ^c   Longley, Daniel B ^d   Bueno, Raphael ^e   Sugarbaker, David J ^e   Fennell, Dean A ^b   Broaddus, V Courtney ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CISPLATIN; PEMETREXED; PROTEIN NOXA; VORINOSTAT;

ARTICLE; BIM GENE; CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; EX VIVO STUDY; GENE SILENCING; HUMAN; HUMAN CELL; MESOTHELIOMA; NOXA GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MESOTHELIOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; SPHEROIDS, CELLULAR; UP-REGULATION;

EID: 84871535784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052753     Document Type: Article

References (29)

1. Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, et al. (2011) The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis 2: e174.
2. Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, et al. (2008) mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 39: 576-583.
3. Yang TM, Barbone D, Fennell DA, Broaddus VC, (2009) Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 41: 14-23.
4. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, et al. (2004) Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9: 573-582.
5. Paik PK, Krug LM, (2010) Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 5: 275-279.
6. Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, et al. (2012) Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer 48: 1096-1107.
7. Khan O, La Thangue NB, (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94.
8. Akimova T, Beier UH, Liu Y, Wang L, Hancock WW, (2012) Histone/protein deacetylases and T-cell immune responses. Blood 119: 2443-2451.
9. Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, et al. (2012) Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 7: 1466-1470.
10. Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, et al. (2011) The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 6: e14640.
11. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, et al. (2011) High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 136: 473-478.
12. Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, et al. (2009) Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ 16: 1146-1155.
13. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, et al. (1992) p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52: 2610-2615.
14. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC, (1998) Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 275: L165-171.
15. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, et al. (1994) Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57: 1395-1401.
16. Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, et al. (2008) CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol 38: 671-678.
17. Barbone D, Yang T, Morgan J, Gaudino G, Broaddus V, (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283: 13021-13030.
18. Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, et al. (2005) A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33: 541-548.
19. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
20. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
21. Ploner C, Kofler R, Villunger A, (2008) Noxa: at the tip of the balance between life and death. Oncogene 27 (Suppl 1):: S84-92.
22. Lopez H, Zhang L, George NM, Liu X, Pang X, et al. (2010) Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem 285: 15016-15026.
23. Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, et al. (2011) Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286: 17682-17692.
24. Xargay-Torrent S, Lopez-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, et al. (2011) Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res 17: 3956-3968.
25. Siegel D, Hussein M, Belani C, Robert F, Galanis E, et al. (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2: 31.
26. Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, et al. (2011) Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 37: 129-135.
27. Perego P, Zuco V, Gatti L, Zunino F, (2012) Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol 83: 987-994.
28. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, et al. (2012) Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18: 783-795.
29. Gryder BE, Sodji QH, Oyelere AK, (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4: 505-524.